A B-és D-vírus hepatitis diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás

Gábor Horváth, B. Hunyady, Judit Gervain, G. Lengyel, Mihály Makara, A. Pár, F. Szalay, L. Telegdy, István Tornai

Research output: Article

5 Citations (Scopus)

Abstract

Diagnosis and treatment of hepatitis B and D virus infections mean that the patient is able to maintain working capacity, increase quality of life, prevent cancer, and prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2014, which is agreed on a consensus meeting of specialists involved in the treatment of the above diseases. The prevalence of hepatitis B virus infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline emphasizes the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection. Orv. Hetil., 2014, 155(Szuppl. 2), 25-35.

Original languageHungarian
Pages (from-to)25-35
Number of pages11
JournalOrvosi Hetilap
Volume155
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2014

Fingerprint

Chronic Hepatitis D
Chronic Hepatitis B
Guidelines
Therapeutics
Lamivudine
Tenofovir
Virus Diseases
Hepatitis B virus
Interferons
Hepatitis D
Hepatitis Delta Virus
Elasticity Imaging Techniques
Costs and Cost Analysis
Immunosuppressive Agents
Hepatitis B Surface Antigens
Life Expectancy
Infection
Nucleic Acids

Keywords

  • adefovir
  • cirrhosis
  • entecavir
  • hepatitis B virus
  • hepatitis D virus
  • interferon
  • lamivudine
  • liver cancer
  • pegylated interferon
  • tenofovir
  • viral hepatitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A B-és D-vírus hepatitis diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. / Horváth, Gábor; Hunyady, B.; Gervain, Judit; Lengyel, G.; Makara, Mihály; Pár, A.; Szalay, F.; Telegdy, L.; Tornai, István.

In: Orvosi Hetilap, Vol. 155, No. SUPPL. 2, 2014, p. 25-35.

Research output: Article

Horváth, Gábor ; Hunyady, B. ; Gervain, Judit ; Lengyel, G. ; Makara, Mihály ; Pár, A. ; Szalay, F. ; Telegdy, L. ; Tornai, István. / A B-és D-vírus hepatitis diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. In: Orvosi Hetilap. 2014 ; Vol. 155, No. SUPPL. 2. pp. 25-35.
@article{448e2e5f6f784d1aa117c1c1b3f8fca2,
title = "A B-{\'e}s D-v{\'i}rus hepatitis diagnosztik{\'a}ja, antivir{\'a}lis kezel{\'e}se. Magyar konszenzusaj{\'a}nl{\'a}s",
abstract = "Diagnosis and treatment of hepatitis B and D virus infections mean that the patient is able to maintain working capacity, increase quality of life, prevent cancer, and prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2014, which is agreed on a consensus meeting of specialists involved in the treatment of the above diseases. The prevalence of hepatitis B virus infection in the Hungarian general population is 0.5-0.7{\%}. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline emphasizes the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection. Orv. Hetil., 2014, 155(Szuppl. 2), 25-35.",
keywords = "adefovir, cirrhosis, entecavir, hepatitis B virus, hepatitis D virus, interferon, lamivudine, liver cancer, pegylated interferon, tenofovir, viral hepatitis",
author = "G{\'a}bor Horv{\'a}th and B. Hunyady and Judit Gervain and G. Lengyel and Mih{\'a}ly Makara and A. P{\'a}r and F. Szalay and L. Telegdy and Istv{\'a}n Tornai",
year = "2014",
doi = "10.1556/OH.2014.29894",
language = "Hungarian",
volume = "155",
pages = "25--35",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "SUPPL. 2",

}

TY - JOUR

T1 - A B-és D-vírus hepatitis diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás

AU - Horváth, Gábor

AU - Hunyady, B.

AU - Gervain, Judit

AU - Lengyel, G.

AU - Makara, Mihály

AU - Pár, A.

AU - Szalay, F.

AU - Telegdy, L.

AU - Tornai, István

PY - 2014

Y1 - 2014

N2 - Diagnosis and treatment of hepatitis B and D virus infections mean that the patient is able to maintain working capacity, increase quality of life, prevent cancer, and prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2014, which is agreed on a consensus meeting of specialists involved in the treatment of the above diseases. The prevalence of hepatitis B virus infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline emphasizes the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection. Orv. Hetil., 2014, 155(Szuppl. 2), 25-35.

AB - Diagnosis and treatment of hepatitis B and D virus infections mean that the patient is able to maintain working capacity, increase quality of life, prevent cancer, and prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2014, which is agreed on a consensus meeting of specialists involved in the treatment of the above diseases. The prevalence of hepatitis B virus infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline emphasizes the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection. Orv. Hetil., 2014, 155(Szuppl. 2), 25-35.

KW - adefovir

KW - cirrhosis

KW - entecavir

KW - hepatitis B virus

KW - hepatitis D virus

KW - interferon

KW - lamivudine

KW - liver cancer

KW - pegylated interferon

KW - tenofovir

KW - viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=84899029854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899029854&partnerID=8YFLogxK

U2 - 10.1556/OH.2014.29894

DO - 10.1556/OH.2014.29894

M3 - Article

C2 - 24631887

AN - SCOPUS:84899029854

VL - 155

SP - 25

EP - 35

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - SUPPL. 2

ER -